open access

Vol 75, No 7 (2017)
Original articles
Published online: 2017-03-31
Submitted: 2016-10-23
Accepted: 2017-03-02
Get Citation

The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis

Hui Li, Yun Zhou, Yan Ma, Suxia Han, Liansuo Zhou
DOI: 10.5603/KP.a2017.0068
·
Kardiol Pol 2017;75(7):666-673.

open access

Vol 75, No 7 (2017)
Original articles
Published online: 2017-03-31
Submitted: 2016-10-23
Accepted: 2017-03-02

Abstract

Background and aim: The aim of this study was to investigate whether the platelet-to-lymphocyte ratio (PLR) is an independent predictor of all-cause mortality and cardiovascular (CV) events in patients with acute coronary syndrome (ACS).

Methods: PubMed, Embase, and the Cochrane Library were searched for relevant cohort studies regarding the association between PLR and outcomes of patients with ACS. Either a random- or a fixed-effect model was used for pooling data.

Results: Eight studies involving 6627 patients with ACS were included. The cut-off PLR value for defining risk groups was 150, and patients were assigned to the low (≤ 150) or high (> 150) PLR groups. The pooled relative risk (RR) values of in-hospital and long-term mortality were 2.15 (95% CI [confidence interval] 1.73–2.67; p < 0.00001) and 2.27 (95% CI 1.35–3.80; p = 0.002), respectively, comparing the high and the low PLR groups. Compared with the low PLR group, the high PLR group had a significantly increased risk of in-hospital (RR 1.95; 95% CI 1.30–2.91; p = 0.001) and long-term (RR 1.50; 95% CI 1.08–2.09; p = 0.01) major adverse CV events.

Conclusions: Elevated PLR was found to be a predictor of all-cause mortality and CV events.

Abstract

Background and aim: The aim of this study was to investigate whether the platelet-to-lymphocyte ratio (PLR) is an independent predictor of all-cause mortality and cardiovascular (CV) events in patients with acute coronary syndrome (ACS).

Methods: PubMed, Embase, and the Cochrane Library were searched for relevant cohort studies regarding the association between PLR and outcomes of patients with ACS. Either a random- or a fixed-effect model was used for pooling data.

Results: Eight studies involving 6627 patients with ACS were included. The cut-off PLR value for defining risk groups was 150, and patients were assigned to the low (≤ 150) or high (> 150) PLR groups. The pooled relative risk (RR) values of in-hospital and long-term mortality were 2.15 (95% CI [confidence interval] 1.73–2.67; p < 0.00001) and 2.27 (95% CI 1.35–3.80; p = 0.002), respectively, comparing the high and the low PLR groups. Compared with the low PLR group, the high PLR group had a significantly increased risk of in-hospital (RR 1.95; 95% CI 1.30–2.91; p = 0.001) and long-term (RR 1.50; 95% CI 1.08–2.09; p = 0.01) major adverse CV events.

Conclusions: Elevated PLR was found to be a predictor of all-cause mortality and CV events.

Get Citation

Keywords

platelet-to-lymphocyte ratio, acute coronary syndrome, all-cause mortality, major adverse cardiovascular events, meta-analysis

About this article
Title

The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 75, No 7 (2017)

Pages

666-673

Published online

2017-03-31

DOI

10.5603/KP.a2017.0068

Bibliographic record

Kardiol Pol 2017;75(7):666-673.

Keywords

platelet-to-lymphocyte ratio
acute coronary syndrome
all-cause mortality
major adverse cardiovascular events
meta-analysis

Authors

Hui Li
Yun Zhou
Yan Ma
Suxia Han
Liansuo Zhou

References (25)
  1. Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J. 2007; 153(1): 29–35.
  2. García-Salas JM, Tello-Montoliu A, Manzano-Fernández S, et al. Interleukin-6 as a predictor of cardiovascular events in troponin-negative non-ST elevation acute coronary syndrome patients. Int J Clin Pract. 2014; 68(3): 294–303.
  3. He Lp, Tang Xy, Ling Wh, et al. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart. 2010; 96(5): 339–346.
  4. Yabluchanskiy A, Ma Y, Iyer RP, et al. Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda). 2013; 28(6): 391–403.
  5. Collet JP, Kerneis M, Hulot JS, et al. GAMMA Investigators. Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. Thromb Haemost. 2016; 115(2): 382–391.
  6. Wu Y, Wu H, Mueller C, et al. Baseline platelet count and clinical outcome in acute coronary syndrome. Circulation J. 2012; 76(3): 704–711.
  7. Núñez J, Sanchis J, Bodí V, et al. Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromes. Eur J Int Med. 2009; 20(8): 768–774.
  8. Ugur M, Gul M, Bozbay M, et al. The relationship between platelet to lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction underwent primary coronary intervention. Blood Coagul Fibrinolysis. 2014; 25(8): 806–811.
  9. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15): 2008–2012.
  10. Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015; 8(1): 2–10.
  11. Gary T, Pichler M, Belaj K, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS One. 2013; 8(7): e67688.
  12. Ayça B, Akin F, Okuyan E. Platelet to lymphocyte ratio as a prognostic marker in primary percutaneous coronary intervention. Platelets. 2015; 26(8): 816–816.
  13. Hudzik B, Szkodzinski J, Gorol J, et al. Platelet-to-lymphocyte ratio is a marker of poor prognosis in patients with diabetes mellitus and ST-elevation myocardial infarction. Biomark Med. 2015; 9(3): 199–207.
  14. Kurtul A, Murat SN, Yarlioglues M, et al. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol. 2014; 114(7): 972–978.
  15. Oylumlu M, Yıldız A, Oylumlu M, et al. Platelet-to-lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome. Anatol J Cardiol. 2015; 15(4): 277–283.
  16. Ozcan Cetin EH, Cetin MS, Aras D, et al. Platelet to lymphocyte ratio as a prognostic marker of in-hospital and long-term major adverse cardiovascular events in st-segment elevation myocardial infarction. Angiology. 2016; 67(4): 336–345.
  17. Temiz A, Gazi E, Güngör Ö, et al. Platelet/lymphocyte ratio and risk of in-hospital mortality in patients with ST-elevated myocardial infarction. Med Sci Monit. 2014; 20: 660–665.
  18. Cho KI, Ann SH, Singh GB, et al. Combined Usefulness of the Platelet-to-Lymphocyte Ratio and the Neutrophil-to-Lymphocyte Ratio in Predicting the Long-Term Adverse Events in Patients Who Have Undergone Percutaneous Coronary Intervention with a Drug-Eluting Stent. PLoS One. 2015; 10(7): e0133934.
  19. Fuentes Q E, Fuentes Q F, Andrés V, et al. Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets. 2013; 24(4): 255–262.
  20. Gonzalez-Porras JR, Martin-Herrero F, Gonzalez-Lopez TJ, et al. The role of immature platelet fraction in acute coronary syndrome. Thromb Haemost. 2010; 103(1): 247–249.
  21. Lindemann S, Krämer B, Seizer P, et al. Platelets, inflammation and atherosclerosis. J Thromb Haemost. 2007; 5 Suppl 1: 203–211.
  22. Choi SW, Choi DH, Kim HW, et al. Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing. Platelets. 2014; 25(5): 322–327.
  23. Verdoia M, Secco GG, Barbieri L, et al. Novara Atherosreclerosis Study Group (NAS). Platelet HPA-1 a/HPA-1 b polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI. Platelets. 2014; 25(5): 367–372.
  24. Bian C, Wu Y, Shi Yu, et al. Predictive value of the relative lymphocyte count in coronary heart disease. Heart Vessels. 2010; 25(6): 469–473.
  25. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013; 11(1): 55–59.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl